Saturday 17 October 2026 Export INDV’s income statement to Excel — free account

Indivior Pharmaceuticals Inc.

INDV Healthcare Drug Manufacturers Specialty & Generic

Indivior Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 4.29% from fiscal 2024. In the quarter to June 2026, revenue grew 13.6%, EPS grew 580.0%, free cash flow grew 58.6% and total debt rose 49.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

32.45 1.17 −3.48%

Follow INDV

Alert me

Market cap: $4.0B
P/E: 11.2×
Fwd P/E: 11.8×
Dividend yield: 0.00%
F-score: 4/9
Altman Z: 3.28
Beneish M: −1.52
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.31

Total sells 2.83

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	5	—	3	—	—	—	—	2	—	—
Sell	—	—	—	—	—	—	—	2	1	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 3,970.00

Revenue 1,331.00

Net Income 356.00

Free Cash Flow (111.00)

Net Debt 265.00

Current Ratio 0.84

Debt/Equity (2.34)

P/E ratio 11.23

Fwd P/E 11.80

P/S ratio 2.90

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 68.86%

Next Y EPS Growth 9.44%

Next Y revenue growth 7.51%

Next 5Y EPS Growth 24.63%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 27.17%

10-year low 10-year high

P/S against its own 10 years 66.68%

10-year low 10-year high

EV/Sales against its own 10 years 84.48%

10-year low 10-year high

Dividends

Payout Ratio 0.00

Annual Dividend Rate 0.00

Annual Dividend Yield 0.00%

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	410	320	195	222
Receivables	254	287	255	287
Inventory	135	167	153	150
Other	467	21	16	54
	1,266	827	652	725

	2023	2024	2025	Q'26
Payables	204	216	250	206
ST’ Debt	3	18	29	—
Other	40	11	—	—
	1,290	924	914	868

Compound Annual Growth %

	10y	5y	3y
Sales	2.02%	13.88%	11.20%
Cash Flow	0.00%	0.00%	0.00%
Earnings	(0.82%)	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	317	343	—	—	—
’25	266	302	314	357	1,239
’24	284	299	307	298	1,188
’23	253	276	271	293	1,093
’22	207	221	232	241	901
’21	180	201	187	223	791
’20	153	150	159	185	647

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	229	—	—	—
’25	75	158	(39)	(221)	(27)
’24	(37)	88	2	(17)	36
’23	(36)	(19)	21	(266)	(300)
’22	(75)	27	62	(18)	(4)
’21	89	71	26	167	353
’20	(146)	(2)	26	(71)	(193)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(29)	222	—	—	—
’25	70	140	(59)	(245)	(94)
’24	(40)	84	(5)	(34)	5
’23	(166)	(20)	(7)	(160)	(353)
’22	(74)	25	60	(19)	(9)
’21	90	40	44	165	339
’20	(146)	(2)	24	(73)	(197)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.69	0.98	—	—	—
’25	0.38	0.14	0.33	0.79	1.64
’24	0.34	(0.79)	0.17	0.16	0.05
’23	0.31	0.27	(0.98)	(0.55)	(0.94)
’22	0.30	0.35	0.28	(1.34)	(0.38)
’21	0.50	0.40	0.15	0.25	1.35
’20	(1.10)	0.12	0.06	(0.10)	(1.00)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	9.80	17.50	4.75	1.75	2.13	6.77	3.13	14.38	7.33	7.62	Analyst estimates 2026–2028 Powerpack
	High	22.60	27.50	33.60	8.10	9.56	18.05	22.00	26.50	23.22	38.00
People
People	Employees	965	1,023	915	796	788	885	953	1,164	1,051	838
	Revenue/emp, $m	1.10	1.07	1.10	0.99	0.82	0.89	0.95	0.94	1.13	1.48
Income, $m
Income, $m	Revenue	1,058	1,093	1,005	785	647	791	901	1,093	1,188	1,239
	Gross margin, %	89.89	90.48	87.26	82.17	85.01	83.94	82.35	84.08	80.56	80.15
	EBT	98	137	278	180	(173)	190	(95)	(149)	20	239
	EBT margin, %	9.26	12.53	27.66	22.93	(26.74)	24.02	(10.54)	(13.63)	1.68	19.29
	Net income	149	193	292	178	(156)	213	(85)	(129)	7	210
	Depreciation	14	13	40	28	26	22	21	15	28	20
Per share, $
Per share, $	Revenue	7.35	7.58	6.91	5.38	4.41	5.43	6.48	7.98	9.00	9.91
	Earnings	0.25	0.40	1.90	0.90	(1.00)	1.40	(0.38)	(0.94)	0.05	1.68
	Cash flow	2.83	2.05	2.08	1.03	(1.32)	2.42	(0.03)	(2.19)	0.27	(0.22)
	Capex	(0.24)	(0.30)	(0.03)	(0.02)	(0.03)	(0.10)	(0.04)	(0.39)	(0.23)	(0.54)
	Free cash flow	2.58	1.75	2.06	1.01	(1.34)	2.33	(0.06)	(2.58)	0.04	(0.75)
	Book value	(2.05)	(1.41)	0.45	1.43	0.56	1.39	0.37	(1.39)	(2.55)	(0.78)
	Shares, m	144	144	145	146	147	146	139	137	132	125
Valuation, ×
Valuation, ×	P/E	71.00	68.75	3.55	2.89	0.00	12.32	0.00	0.00	0.00	21.23
	P/S	2.42	3.63	0.98	0.48	1.66	3.18	3.36	1.94	1.38	3.62
	P/B	0.00	0.00	14.87	1.82	13.10	12.38	59.28	0.00	0.00	0.00
	EV/Sales	2.27	3.28	0.30	(0.56)	0.70	2.09	2.63	1.78	1.39	3.72
	EV/FCF	6.52	15.13	1.00	(3.02)	(2.26)	4.90	(237.05)	(5.52)	330.75	(48.52)
Cash, $m
Cash, $m	Operating cash flow	407	295	303	151	(193)	353	(4)	(300)	36	(27)
	Capex	(35)	(43)	(4)	(3)	(4)	(14)	(5)	(53)	(31)	(67)
	Free cash flow	372	252	299	148	(197)	339	(9)	(353)	5	(94)
Balance, $m
Balance, $m	Working capital	(40)	371	511	618	588	640	240	(24)	(97)	(262)
	Total debt	535	482	241	237	234	242	240	240	333	319
	Net debt	(157)	(381)	(683)	(823)	(624)	(860)	(653)	(170)	13	124
	Shareholders’ equity	(295)	(203)	66	209	82	203	51	(191)	(337)	(98)
Returns, %
Returns, %	ROA	3.26	4.37	18.39	8.38	(9.30)	12.19	(2.94)	(7.31)	0.46	16.69
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	629.81
	ROE	(12.20)	(23.29)	(401.46)	97.45	(101.72)	143.86	(41.73)	182.98	(2.65)	(96.33)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 2 Oct 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ALKS Alkermes plc	$6.7B	102×	— (loss-making)	+26.97% (above 0%: growing)	−99.43% (below 0%: shrinking)	+1.13% (above 0%: growing)	80.22%	3.70%	Compare
LNTH Lantheus Holdings, Inc.	$6.5B	23.7×	25.3×	+2.68% (above 0%: growing)	0.00%	+13.55% (above 0%: growing)	62.30%	25.82%	Compare
KNSA Kiniksa Pharmaceuticals International, plc	$6.2B	73.4×	38.7×	+55.36% (above 0%: growing)	+37.50% (above 0%: growing)	+66.63% (above 0%: growing)	90.32%	11.16%	Compare
AMRX AMNEAL PHARMACEUTICALS, INC.	$6.2B	38.4×	51.6×	+9.89% (above 0%: growing)	+157.14% (above 0%: growing)	−351.41% (below 0%: shrinking)	42.01%	16.30%	Compare
RGC Regencell Bioscience Holdings Limited	$4.7B	— (loss-making)	—	—	—	+57.15% (above 0%: growing)	0.00%	—	Compare
INDV Indivior Pharmaceuticals Inc.	$4.0B	11.2×	11.8×	+13.58% (above 0%: growing)	+580.00% (above 0%: growing)	+58.57% (above 0%: growing)	85.42%	46.36%
AMLX Amylyx Pharmaceuticals, Inc.	$3.5B	— (loss-making)	— (loss-making)	−100.61% (below 0%: shrinking)	n/m	−24.50% (below 0%: shrinking)	100.00%	0.00%	Compare
LQDA Liquidia Corporation	$3.1B	21.9×	18.5×	+1,842.73% (above 0%: growing)	n/m	+270.23% (above 0%: growing)	93.27%	49.81%	Compare
HCM HUTCHMED (China) Limited Sponsored ADR	$2.4B	— (loss-making)	—	+510.07% (above 0%: growing)	+419.25% (above 0%: growing)	+113.21% (above 0%: growing)	60.90%	0.00%	Compare
Median of peers	$5.4B	38.4×	32.0×	+26.97%	+37.50%	+35.35%	71.26%	11.16%

All 86 Drug Manufacturers Specialty & Generic stocks →